Clinical Trial Update: Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

This document describes a Phase 2 trial evaluating neoadjuvant sunitinib for metastatic clear cell renal cell carcinoma; the current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Korean Urological Oncology Society | Conditions: Clear Cell Renal Cell Carcinoma, Metastasis | Phase 2 | Status: UNKNOWN